Donna Cullen Greene - Mar 3, 2022 Form 4 Insider Report for NEXTGEN HEALTHCARE, INC. (NXGN)

Role
EVP, Human Resources
Signature
/s/Jeffrey D. Linton, Attorney-in-Fact for Donna Cullen Greene
Stock symbol
NXGN
Transactions as of
Mar 3, 2022
Transactions value $
-$314,714
Form type
4
Date filed
3/4/2022, 06:12 PM
Previous filing
Dec 28, 2021
Next filing
Jun 28, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NXGN Common Stock Options Exercise $166K +10K +16.82% $16.64 69.5K Mar 3, 2022 Direct
transaction NXGN Common Stock Options Exercise $84.7K +6.63K +9.54% $12.78 76.1K Mar 3, 2022 Direct
transaction NXGN Common Stock Options Exercise $278K +17K +22.34% $16.37 93.1K Mar 3, 2022 Direct
transaction NXGN Common Stock Options Exercise $431K +30K +32.23% $14.38 123K Mar 3, 2022 Direct
transaction NXGN Common Stock Sale -$1.28M -63.6K -51.69% $20.05 59.5K Mar 3, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NXGN Stock Option (right to buy) Options Exercise $0 -10K -15.72% $0.00 53.6K Mar 3, 2022 Common Stock 10K $16.64 Direct F2
transaction NXGN Stock Option (right to buy) Options Exercise $0 -6.63K -12.35% $0.00 47K Mar 3, 2022 Common Stock 6.63K $12.78 Direct F3
transaction NXGN Stock Option (right to buy) Options Exercise $0 -17K -36.17% $0.00 30K Mar 3, 2022 Common Stock 17K $16.37 Direct F4
transaction NXGN Stock Option (right to buy) Options Exercise $0 -30K -100% $0.00* 0 Mar 3, 2022 Common Stock 30K $14.38 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.16 to $19.99. Full information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or its stockholders upon request.
F2 Original grant of 10,000 options granted on 5/22/2015 vested in five equal, annual installments beginning 5/22/2016.
F3 Original grant of 26,500 options granted on 5/25/2016 vested in four equal, annual installments beginning 5/25/2017.
F4 Original grant of 20,000 options granted on 6/13/2017 vested in four equal, annual installments beginning 6/13/2018.
F5 Original grant of 40,000 options granted on 12/4/2017 vested in four equal, annual installments beginning 12/4/2018.